RAR? gene methylation is a candidate for primary glioblastoma treatment planning.

Basit Öğe Kaydı
dc.authoridArtan, Sevilhan/0000-0001-7658-6309
dc.authoridAydin, Hasan Emre/0000-0002-8932-1542
dc.authoridatli, emine ikbal/0000-0001-9003-1449
dc.authoridKalkan, Rasime/0000-0002-6095-7352
dc.authorwosidArtan, Sevilhan/AEG-2575-2022
dc.authorwosidAydin, Hasan Emre/AAA-4657-2021
dc.authorwosidatli, emine ikbal/AAN-5060-2020
dc.authorwosidKalkan, Rasime/X-4808-2019
dc.contributor.authorAtli, Emine Ikbal
dc.contributor.authorKalkan, Rasime
dc.contributor.authorOzdemir, Muhsin
dc.contributor.authorAydin, Hasan Emre
dc.contributor.authorArslantas, Ali
dc.contributor.authorArtan, Sevilhan
dc.date.accessioned2024-06-12T11:13:23Z
dc.date.available2024-06-12T11:13:23Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: We screened RAR beta methylation in primary glioblastoma multiforme (GBM) and the results were evaluated based on the clinical data and treatment type. Objective: The objective of this study was to find new areas for the usage of MS-HRM applications in the determination of methylation levels in primary GBM samples and it shows the association of RAR beta methylation with the clinical outcome. Methods: In our study, tumor samples were collected during surgical resection by the Department of Neurosurgery. The clinical and radiologic data was carefully reviewed, compared, and evaluated with the histological results. The methylation status of RAR beta was determined by using MS-HRM. Results: RAR beta gene methylation was detected in 24 out of 40 cases (60%), with different quantitative methylation levels. The mean survival time was 19 months form ethylated cases and 15 months for the non-methylated cases. The survival time of the patients who received treatment was 25 months and the survival time of the patients who received radiotherapy alone or where no treatment protocol applied was 15-20 months. Therefore, a significant difference in survival rates has been observed (P< 0.05). This study indicates a potential prognostic value for GBM treatment planning. Conclusion: Our study is the first study to investigate RAR beta methylation in primary GBMs. We conclude that the RAR beta gene could be a new prognostic and predictive candidate marker to designate the treatment protocol for primary GBMs.en_US
dc.description.sponsorshipEskisehir Osmangazi University, Eskisehir, Turkey; [201011034]en_US
dc.description.sponsorshipThis study was supported by grants from Eskisehir Osmangazi University, Eskisehir, Turkey and the project number was 201011034.en_US
dc.identifier.doi10.4314/ahs.v16i1.29
dc.identifier.endpage226en_US
dc.identifier.issn1680-6905
dc.identifier.issn1729-0503
dc.identifier.issue1en_US
dc.identifier.pmid27358635en_US
dc.identifier.scopus2-s2.0-84966280694en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage218en_US
dc.identifier.urihttps://doi.org/10.4314/ahs.v16i1.29
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23530
dc.identifier.volume16en_US
dc.identifier.wosWOS:000378847700029en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMakerere Univ, Fac Meden_US
dc.relation.ispartofAfrican Health Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRAR Betaen_US
dc.subjectPrimary Glioblastoma Multiformeen_US
dc.subjectMethylationen_US
dc.subjectMS-HRMen_US
dc.subjectDna Methylationen_US
dc.subjectGliomasen_US
dc.titleRAR? gene methylation is a candidate for primary glioblastoma treatment planning.en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu